Micro Emerging Active

HCA trims FY26 EPS outlook

New narrative with limited coverage — still forming.

Score
0.3
Velocity
▲ 0.0
Articles
3
Sources
2

Top Movers

TickerSectorChange
Health Care+2.7%
🤖

AI Overview

What happened: On July 24, HCA Healthcare (HCA) reported Q2 2026 results, confirming earlier guidance. While revenues grew, payer mix deteriorated, leading HCA to trim its full-year EPS outlook to $28.70-$30.50. AbbVie (ABBV) also reduced its FY26 adjusted EPS guidance to $13.87-$14.07.

Market impact: The revisions impacted healthcare stocks. HCA's guidance cut raised concerns about profit margins, affecting other hospital operators like Tenet Healthcare (THC) and Universal Health Services (UHS). AbbVie's guidance reduction pressured other pharma stocks, such as Merck (MRK) and Bristol-Myers Squibb (BMY), due to potential pricing pressures.

What to watch next: Investors await HCA's Q3 2026 earnings (Oct 25) for further clarity on payer mix trends. AbbVie's Q3 2026 earnings (Oct 26) will provide updates on its cost-cutting efforts. Additionally, monitor the FDA's decision on AbbVie's Rinvoq (Oct 28), which could impact its revenue outlook.
AI Overview as of Aug 15, 2026

Timeline

First SeenAug 15, 2026
Last UpdatedAug 22, 2026